CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-93269

First Posted Date: 2018-04-03

Last Posted Date: 2024-05-30

Lead Sponsor: Celgene

Target Recruit Count: 250

Registration Number: NCT03486067

Locations: 🇺🇸
Local Institution - 106, Atlanta, Georgia, United States
🇺🇸
Local Institution - 111, Boston, Massachusetts, United States
🇺🇸
Local Institution - 101, Seattle, Washington, United States

and more 31 locations

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: JCAR017

First Posted Date: 2018-04-02

Last Posted Date: 2024-01-12

Lead Sponsor: Celgene

Target Recruit Count: 113

Registration Number: NCT03484702

Locations: 🇮🇹
Local Institution - 402, Milan, Italy
🇬🇧
Local Institution - 501, London, United Kingdom
🇬🇧
Local Institution - 502, Manchester, Lancashire, United Kingdom

and more 17 locations

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

Interventions: Drug: Ozanimod

First Posted Date: 2018-03-16

Last Posted Date: 2024-11-26

Lead Sponsor: Celgene

Target Recruit Count: 854

Registration Number: NCT03467958

Locations: 🇺🇸
Holland Center for Family Health, Peoria, Arizona, United States
🇺🇸
Local Institution - 202, Scottsdale, Arizona, United States
🇺🇸
Local Institution - 026, North Little Rock, Arkansas, United States

and more 760 locations

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Phase 3

Terminated

Conditions: Crohn Disease

Interventions: Drug: Ozanimod
Other: Placebo

First Posted Date: 2018-03-13

Last Posted Date: 2024-11-04

Lead Sponsor: Celgene

Target Recruit Count: 551

Registration Number: NCT03464097

Locations: 🇺🇸
Local Institution - 141, Middleburg Heights, Ohio, United States
🇺🇸
Holland Center for Family Health, Peoria, Arizona, United States
🇺🇸
Local Institution - 202, Scottsdale, Arizona, United States

and more 759 locations

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

Interventions: Other: Placebo
Drug: Ozanimod

First Posted Date: 2018-02-22

Last Posted Date: 2024-12-05

Lead Sponsor: Celgene

Target Recruit Count: 606

Registration Number: NCT03440385

Locations: 🇫🇮
Local Institution - 614, Turku, Finland
🇺🇸
Local Institution - 202, Scottsdale, Arizona, United States
🇺🇸
Ucsd Medical Center, La Jolla, California, United States

and more 365 locations

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Phase 3

Terminated

Conditions: Crohn Disease

Interventions: Drug: Ozanimod
Other: Placebo

First Posted Date: 2018-02-22

Last Posted Date: 2024-11-18

Lead Sponsor: Celgene

Target Recruit Count: 625

Registration Number: NCT03440372

Locations: 🇲🇽
Local Institution - 525, Monterrey, Nuevo León, Mexico
🇮🇳
Local Institution - 443, Jaipur, Rajasthan, India
🇲🇽
Local Institution - 532, Monterrey, Nuevo León, Mexico

and more 405 locations

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

Completed

Conditions: Leukemia, Myeloid, Acute

First Posted Date: 2018-02-19

Last Posted Date: 2021-05-21

Lead Sponsor: Celgene

Target Recruit Count: 151

Registration Number: NCT03435341

Locations: 🇪🇸
Hospital de León, León, Castilla-León, Spain
🇪🇸
Hospital Virgen de las Nieves, Granada, Andalucía/Granada, Spain
🇪🇸
Hospital Universitario Nuestra Señora de Valme, Sevilla, Andalucía/Sevilla, Spain

and more 37 locations

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Phase 2

Recruiting

Conditions: Neoplasms

Interventions: Genetic: Gene-modified (GM) T cell therapy

First Posted Date: 2018-02-19

Last Posted Date: 2024-08-07

Lead Sponsor: Celgene

Target Recruit Count: 317

Registration Number: NCT03435796

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Local Institution - 01206, Los Angeles, California, United States

and more 170 locations

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-92480
Drug: Dexamethasone

First Posted Date: 2017-12-15

Last Posted Date: 2024-12-16

Lead Sponsor: Celgene

Target Recruit Count: 201

Registration Number: NCT03374085

Locations: 🇺🇸
Local Institution - 103, Duarte, California, United States
🇺🇸
Local Institution - 102, Atlanta, Georgia, United States
🇺🇸
Local Institution - 105, Boston, Massachusetts, United States

and more 51 locations

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Heathy Volunteer

Interventions: Drug: CC-90001
Drug: Omeprazole
Drug: Nintedanib
Drug: Rosuvastatin
Drug: Metformin
Drug: Midazolam
Drug: Digoxin
Drug: Warfarin
Dietary Supplement: Vitamin K

First Posted Date: 2017-12-06

Last Posted Date: 2019-01-25

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT03363815

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy